Earnings release
Page 1
EXHIBIT 99.1 BIOAGE BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL - CV , a Phase 2 dose - ranging proof - of - concept trial of BGE - 102 measuring inflammatory and cardiometabolic biomarkers ; topline data anticipated in the second half of 2026 QUELL - DME , Phase 1b / 2a proof - of - concept trial of BGE - 102 in diabetic macular edema , planned to initiate in mid - 2026 , with data anticipated in mid - 2027 ; results expected to support development across inflammation - driven retinal diseases Hosted R & D Day focused on NLRP3 inhibition , featuring Phase 1 data for BGE - 102 EMERYVILLE , Calif . , August 5 , 2026 ( GLOBE NEWSWIRE ) -- BioAge Labs , Inc. ( NASDAQ : BIOA ) ( " BioAge " or " the Company " ) , a clinical - stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging , today provided business updates and reported its second quarter 2026 financial results . " NLRP3 sits at the apex of the inflammatory cascade that drives a range of diseases , " said Kristen Fortney , Ph.D. , CEO and co - founder of BioAge . " Our Phase 1 data show that BGE - 102 is a potential best - in - class NLRP3 inhibitor : a well - tolerated once - daily pill that delivered up to 98 % suppression of IL- 1ß and brought hsCRP down to normal levels in most participants . We have dosed the first participant in QUELL - CV , our Phase 2 trial in patients with obesity and inflammation at elevated cardiovascular risk , with topline data anticipated in the second half of 2026. We also plan to start a second proof - of - concept trial this year in diabetic macular edema . These studies will test the broad potential of NLRP3 inhibition across inflammasome - driven diseases , and we are actively evaluating additional indications where this mechanism can deliver meaningful benefit . With a strong cash position , we are well positioned to advance BGE - 102 across multiple opportunities and continue progressing the broader BioAge pipeline . "